
Oncology NEWS International
- Oncology NEWS International Vol 12 No 2
 - Volume 12
 - Issue 2
 
ILEX Begins Phase I/II Trial of Campath in CD52-Positive NHL
SAN ANTONIO-ILEX Oncology, Inc. has launched the first ILEX-sponsored study of Campath (alemtuzumab) in patients with CD52-antigen-positive relapsing or refractory non-Hodgkin’s lymphoma (NHL). Campath is a humanized monoclonal antibody directed against the CD52 antige
SAN ANTONIOILEX Oncology, Inc. has launched the first ILEX-sponsored study of Campath (alemtuzumab) in patients with CD52-antigen-positive relapsing or refractory non-Hodgkin’s lymphoma (NHL). Campath is a humanized monoclonal antibody directed against the CD52 antigen.
The trial, designed to determine the appropriate dose in a weekly schedule, marks the first time ILEX is studying Campath in a disease in which the CD52 antigen appears to be highly expressed, the company said in a news release. Campath is FDA approved for patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and have failed fludarabine (Fludara) treatment.
Articles in this issue
almost 23 years ago
Some Activity for Gefitinib in Heavily Pretreated Breast Canceralmost 23 years ago
Brachytherapy Results Similar for Blacks, Whitesalmost 23 years ago
Dose-Dense Chemo Ups Survival in Node+ Breast Canceralmost 23 years ago
MR Spectroscopy IDs Breast Cancers, Node Involvementalmost 23 years ago
ODAC Wants More Data on Expanded Casodex Indicationalmost 23 years ago
SuperGen Submits First NDA Module for Pancreatic Cancer Drugalmost 23 years ago
Two Added to ONI’s Oncology Nursing Editorial Advisory Boardalmost 23 years ago
Bortezomib Active in Relapsed/Refractory Myelomaalmost 23 years ago
Telomerase Potential Cancer BiomarkerNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



















































































